[{"data":1,"prerenderedAt":169},["ShallowReactive",2],{"content-route-/en/research/genital-cutaneous-candidiasis-vs-recurrent-vvc-2025":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":151,"alternates":160},"target","/en/research/genital-cutaneous-candidiasis-vs-recurrent-vvc-2025","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":59,"body":63},"Recurrent vaginal yeast infection: 8 guidelines compared","A 2025 review compares 8 guidelines on recurrent vaginal yeast infection: two use 3 episodes/year, six use 4; the proposed split is unvalidated.","2026-10-08","Initial publication; contextual review summary adds no clinical outcome or practical change.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":41,"limitations":48,"practicalChange":58},"day-genital-cutaneous-vs-rvvc-2025","Narrative and conceptual review comparing selected guidelines","Eight selected national and international guideline documents and heterogeneous cited literature; no recruited participant population.","Eight selected guidelines; no primary participant cohort or original clinical outcome dataset.","contextual","The review documents variation in recurrence thresholds and confirmation descriptions and proposes a vaginal-versus-vulvar phenotype framework. It has no primary clinical outcomes, and its proposed distinction is not a validated classification, so it adds context without changing the broader evidence map or practical guidance.","/en/research/evidence/recurrent-vaginal-yeast-symptoms","The authors reported that this work received no funding.","The authors declared no conflict of interest.","2025-05-28",[38,39,40],"Of the eight selected guideline entries, CDC and ISSVD use at least three symptomatic episodes per year for recurrent vulvovaginal candidiasis (VVC); the other six use at least four per year.","Table 1 lists microscopy, culture, or NAAT as ISSVD confirmation options without an explicit requirement, while the review prose says a positive culture is crucial before therapy. The review does not resolve this table/prose discrepancy or establish one universal test rule.","The narrative review reports no primary participant cohort, pooled or comparative clinical outcomes, or clinical treatment or safety finding; it provides no absolute outcome estimate with a denominator.",{"appliesTo":42,"doesNotApplyTo":45},[43,44],"Understanding that recurrence thresholds and confirmation descriptions vary across the eight guidelines selected by the review.","Understanding the authors' proposed distinction between estrogen-dependent vaginal VVC and estrogen-independent vulvar cutaneous candidiasis as a conceptual framework.",[46,47],"Establishing a validated or universally adopted disease classification, or deciding whether a person's symptoms arise from vaginal or vulvar disease.","Setting a universal episode threshold or confirmation test, selecting treatment, or determining treatment safety.",[49,52,55],{"finding":50,"limitation":51},"The authors present a narrative and conceptual review.","No systematic search databases or dates, reproducible eligibility criteria, screening flow, or formal risk-of-bias assessment are reported, so review completeness cannot be judged.",{"finding":53,"limitation":54},"Table 1 compares eight selected national and international guidelines.","The guidelines are heterogeneous and do not form a complete global inventory; the review's ISSVD confirmation table and prose do not agree.",{"finding":56,"limitation":57},"The review proposes estrogen-dependent vaginal VVC and estrogen-independent vulvar cutaneous candidiasis as distinct phenotypes.","The authors' framework is not a validated classification, and no primary cohort or comparative clinical outcome data establish its prognosis or treatment implications.","No practical change. The review does not establish a new universal recurrence threshold, confirmation rule, diagnosis, treatment choice, or safety action.",[60],{"group":61,"route":33,"label":62},"evidence","Recurrent vaginal yeast symptoms evidence map",{"type":64,"value":65,"toc":147},"minimark",[66,74,80,86,92,104,110,116,122,128,134],[67,68,70],"content-section",{"section-key":10,"title":69},"Bottom line",[71,72,73],"p",{},"This narrative review compared eight selected guidelines. Two define recurrent vulvovaginal candidiasis (VVC) as at least three symptomatic episodes in a year; six use at least four. It adds no clinical outcome data or treatment or safety finding, so it does not change practical guidance.",[67,75,77],{"section-key":11,"title":76},"Why this source matters",[71,78,79],{},"The review makes differences in recurrence thresholds and confirmation language visible. Its proposed distinction between vaginal disease and vulvar skin disease remains a conceptual framework, not a validated classification.",[67,81,83],{"section-key":12,"title":82},"Study type and population",[71,84,85],{},"This is a narrative and conceptual review of eight selected guidelines and cited literature, not a study that recruited participants. The populations discussed come from heterogeneous cited sources; the review has no single participant cohort.",[67,87,89],{"section-key":13,"title":88},"What was examined",[71,90,91],{},"The authors compared guideline definitions and descriptions of recurrent VVC and proposed two phenotypes: estrogen-dependent vaginal VVC and estrogen-independent vulvar cutaneous candidiasis. This is the review authors' proposed framework; it has not been validated or uniformly adopted.",[67,93,95,98,101],{"section-key":14,"title":94},"Results",[71,96,97],{},"Among the eight selected guidelines, CDC and ISSVD use a threshold of at least three symptomatic episodes per year; the other six use at least four. The review also describes variation in confirmation requirements.",[71,99,100],{},"For ISSVD, Table 1 lists microscopy, culture, or NAAT as options without an explicit requirement. The surrounding prose says that a positive culture is crucial before therapy. The authors do not reconcile this table/prose discrepancy, so the review does not establish one universal test rule.",[71,102,103],{},"There is no primary participant cohort, pooled or comparative clinical outcome, or clinical treatment or safety finding in this review. It reports no absolute clinical outcome estimate with a denominator.",[67,105,107],{"section-key":15,"title":106},"Applicability",[71,108,109],{},"The review can help readers understand why selected guidelines describe recurrence and confirmation differently. Its proposed estrogen-dependent vaginal versus estrogen-independent vulvar cutaneous distinction is an author-proposed framework, not a validated way to classify an individual person's symptoms.",[67,111,113],{"section-key":16,"title":112},"Limitations",[71,114,115],{},"The article reports no systematic search methods, screening flow, or formal risk-of-bias assessment. Its eight selected guidelines are heterogeneous and are not a complete global inventory. The proposed phenotype distinction has not been validated, and the review has no primary cohort or comparative outcome data to establish prognosis, treatment effects, or safety.",[67,117,119],{"section-key":17,"title":118},"Contribution to the evidence",[71,120,121],{},"Contextual contribution. The review documents variation in guideline definitions and confirmation descriptions, but does not change the broader evidence map or establish a new diagnostic classification.",[67,123,125],{"section-key":18,"title":124},"Practical change",[71,126,127],{},"No practical change. This review does not establish a new universal episode threshold, confirmation rule, diagnosis, treatment choice, or safety action.",[67,129,131],{"section-key":19,"title":130},"Funding and conflicts",[71,132,133],{},"The authors reported that the work received no funding and declared no conflict of interest.",[67,135,137],{"section-key":20,"title":136},"Source",[71,138,139,146],{},[140,141,145],"a",{"href":142,"rel":143},"https://pmc.ncbi.nlm.nih.gov/articles/PMC12160500/",[144],"nofollow","Read the original publication"," (published 28 May 2025; issue date 12 June 2025).",{"title":148,"searchDepth":149,"depth":149,"links":150},"",2,[],{"sources":152,"claims":158,"safety":159},[153],{"sourceId":27,"title":154,"canonicalId":155,"canonicalUrl":142,"publisher":156,"sourceType":157,"publicationDate":36,"lastChecked":24},"Genital cutaneous candidiasis versus chronic recurrent vulvovaginal candidiasis: distinct diseases, different populations","PMID:40434101; DOI:10.1128/cmr.00020-25","Clinical Microbiology Reviews","other",[],[],[161,164,167],{"rel":162,"hreflang":6,"href":163},"alternate","https://candipedia.org/en/research/genital-cutaneous-candidiasis-vs-recurrent-vvc-2025/",{"rel":162,"hreflang":165,"href":166},"pl-PL","https://candipedia.org/pl/research/grzybica-skory-sromu-a-nawracajaca-grzybica-pochwy-2025/",{"rel":162,"hreflang":168,"href":163},"x-default",1791487498294]